Treatment of cutaneous candidiasis through fluconazole encapsulated cubosomes

Drug Delivery and Translational Research
Vijay PrajapatiDharm Veer Kohli

Abstract

Cubosomes encapsulating fluconazole were prepared by emulsification method and characterized for particle size, entrapment efficiency, SEM, in vitro release, skin irritation studies, and confocal laser scanning microscopy. The cubosomes prepared were 257.2 ± 2.94 nm in size and with drug entrapment efficiency of 66.2 ± 2.69 %. The prepared formulation was characterized for surface morphology by SEM analysis which revealed their smooth surface. The cumulative percentage of fluconazole from cubosomes permeated via dialysis membrane (molecular weight cutoff (MWCO) 12-14 kD) showed 76.86 % cumulative drug release, while fluconazole solution showed release up to 91.04 % in 24 h in phosphate-buffered saline (PBS) (pH 6.5), and sustained release is obtained after 24 h in case of cubosomes. The animal studies also revealed that the cubosomes are non-irritant and have sustained antifungal activity.

References

Jan 1, 1987·Dermatologica·W Wohlrab, J Lasch
Aug 1, 1994·Journal of Chemotherapy·M P ArévaloA Sierra
Apr 1, 1993·Journal of Microencapsulation·M SinghH Atwal
Dec 10, 1999·The Journal of Antimicrobial Chemotherapy·M V Martin
Jun 3, 2005·Chemical & Pharmaceutical Bulletin·Mei-Ying NingZhong-Wei Gu
Aug 12, 2005·Drug Development and Industrial Pharmacy·Meiying NingZhongwei Gu
Feb 2, 2006·The Journal of Antimicrobial Chemotherapy·C CharlierO Lortholary
Feb 3, 2007·Biological & Pharmaceutical Bulletin·Gopal GargSwarnlata Saraf
Sep 18, 2008·Drug Development and Industrial Pharmacy·Mona M A Abdel-MottalebG A S Awad
Mar 29, 2013·Journal of Microencapsulation·Aakanchha JainN K Jain
Jun 26, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Juana SchwartzSocorro Espuelas

❮ Previous
Next ❯

Citations

Sep 5, 2020·Expert Opinion on Drug Delivery·Ana Vitoria Pupo SilvestriniMaria Vitoria Lopes Badra Bentley
Aug 17, 2020·Critical Reviews in Microbiology·Victor Hugo Sousa AraujoMarlus Chorilli
May 20, 2017·Journal of Drug Targeting·Mahima Mathur, V Kusum Devi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.